Latest news

• Real-world data finds patients feel better on Entresto, says Novartis

  Lokelma (sodium zirconium cyclosilicate or ZS-9) and Vifor Pharma’s Veltassa (patiromer) which “will be a particularly valuable addition to the clinic if efficacy can be confirmed in clinical trials”.

• AZ gets US approval for Veltassa rival Lokelma

  Lokelma (sodium zirconium cyclosilicate or ZS-9) has been cleared by the FDA as an oral treatment for hyperkalaemia (elevated potassium levels) in adults, a potentially life-threatening condition caused by

• AZ finally gets EU nod for Veltassa rival Lokelma

  Lokelma (sodium zirconium cyclosilicate or ZS-9) has been approved for adults with hyperkalaemia, a potentially life-threatening condition which can cause cardiac arrest and muscle paralysis, allowing it to finally

• Vifor wins European approval for Veltassa

  cyclosilicate) in February.

• FDA turns down AZ's ZS-9 once again on manufacturing issues

  The US regulator issued a Complete Response Letter to ZS Pharma regarding its application for ZS-9 (sodium zirconium cyclosilicate) as a treatment for the condition - known as hyperkalaemia - after an